The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation

Author(s): A. Sgambato, F. Casaluce, P. Maione, A. Rossi, E. Rossi, A. Napolitano, G. Palazzolo, M. A. Bareschino, C. Schettino, P. C. Sacco, F. Ciadiello, C. Gridelli.

Journal Name: Current Medicinal Chemistry

Volume 19 , Issue 20 , 2012

Become EABM
Become Reviewer

Abstract:

Lung cancer continues to be the leading cause of cancer death worldwide. Among lung cancers, 80% are classified as nonsmall- cell lung cancer (NSCLC) and are mostly diagnosed at an advanced stage (either locally advanced or metastatic disease). In the last years, the discovery of the pivotal role in tumorigenesis of the Epidermal Growth Factor Receptor (EGFR) has provided a new class of targeted therapeutic agents: the EGFR tyrosine kinase inhibitors (EGFR-TKIs). Since the first reports of an association between somatic mutations in EGFR exons 19 and 21 and response to EGFR-TKIs, treatment of advanced NSCLC has changed dramatically. Histologic profile, clinical characteristics, and mutational profile of lung carcinoma have all been reported as predictive factors of response to EGFR-TKIs and other targeted therapies. In advanced NSCLC patients harboring EGFR mutations, the use of EGFR TKIs in first-line treatment has provided an unusually large progression-free survival (PFS) benefit with a negligible toxicity when compared with cytotoxic chemotherapy in phase III randomized trials. Considering the findings regarding the excellent benefit and better safety profile of EGFR TKIs in EGFR mutation positive patients, these targeted therapeutic agents can be now considered as first-line treatment in this setting of patients. This review will discuss the new evidences in the role of EGFR-TKIs in the first-line treatment of advanced NSCLC and their implication in the current clinical decision-making.

Keywords: Acquired resistance, advanced NSCLC, epidermal growth factor mutation, erlotinib, first-line treatment, fluorescence in situ hybridization, gefitinib, immunohistochemistry, mutation detection, primary resistance, polymerase chain reaction, targeted therapy

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 20
Year: 2012
Page: [3337 - 3352]
Pages: 16
DOI: 10.2174/092986712801215973
Price: $58

Article Metrics

PDF: 49